Fosinopril (SQ28555 free acid) is the ester prodrug ofangiotensin-converting enzyme(ACE) inhibitor with anIC₅₀value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect onACEactivity with anK_ivalue of 1.675 μM^[1][2].

IC50: 0.18 μM^[1]; Ki: 1.675 μM^[2]

Fosinopril (0-100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2^[1].
Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2^[1].
Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with an K_ivalue of 1.675 μM^[2].

Fosinopril (4.67 mg/kg; p.o.; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and againsts cardiac dysfunction and structural alteration in rat^[3].
Fosinopril (4.67 mg/kg; p.o.; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model^[3].

563.66

C₃₀H₄₆NO₇P

98048-97-6

福辛普利

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.